Anti-CTLA4: Issues in Development and Regulatory Approval
November 2, 2008
Westin Gaslamp Quarter Hotel
San Diego, CA
Presentation Slides & Schedule
Slides for select presentations below have been provided by the corresponding speaker for your convenience.
Please click the 
next to the speaker's name to log in to view presentations.
| Sunday, November 2, 2008 | |
| 10:30 am - 10:35 am | Introduction Ulrich Keilholz, MD - Charité CBF |
| 10:35 am - 10:45 am | Review of Ipilmumab Development Program and Data Jeffrey S. Weber, MD, PhD - H. Lee Moffitt Cancer Center and Research Institute
|
| 10:45 am - 10:55 am | Review of Tremilmumab Development Program and Data Antoni Ribas, MD - UCLA Medical Center |
| 10:55 am - 11:05 am | Comparison of Development Plans of IL2 and CTLA4 Abs Mario Sznol, MD - Yale University School of Medicine |
| 11:05 am - 11:15 am | Evaluation of IL2/Anti-CTLA4 Type Activity Data Steven Hirschfeld, MD, PhD - National Institute of Child Health and Human Development |
| 11:15 am - 11:20 am | Introduction into the Panel and Audience Discussion Michael B. Atkins, MD - Beth Israel Deaconess Medical Center |
| 11:20 am - 11:59 am | Panel Discussion / Audience Questions |
| 11:59 am - 12:00 pm | Closing Remarks Ulrich Keilholz, MD - Charité CBF |
| 12:00 pm | Adjourn |
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
